Nello Mainolfi - 08 Dec 2022 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Role
Chief Executive Officer, Director
Signature
/s/ Bruce N. Jacobs, as Attorney-in-Fact
Issuer symbol
KYMR
Transactions as of
08 Dec 2022
Net transactions value
+$20,800
Form type
4
Filing time
08 Dec 2022, 17:11:29 UTC
Previous filing
17 Oct 2022
Next filing
03 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KYMR Common Stock Options Exercise $20,800 +10,000 +1.8% $2.08* 573,700 08 Dec 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KYMR Stock Option (Right to Buy) Options Exercise $0 -10,000 -35% $0.000000 18,725 08 Dec 2022 Common Stock 10,000 $2.08 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This number includes 1,769 shares acquired under the Registrant's employee stock purchase plan on December 1, 2022.
F2 The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones.